Ricevi le ultime notizie sulle azioni PureTech Health con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di PRTC

Ultime notizie per

PureTech Health

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

PureTech Health plc - American Depositary Shares

PureTech Health PLC

Press Releases

PureTech Announces Leadership Transition

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress

PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases

PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

PureTech Health: Notice of Half-Yearly Results

PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF

PureTech Health plc – Half-Year Report

PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers

Penny Stocks

Small Cap

Biotech Stocks Positioned to Transform Treatment With Next-Gen Therapeutics

PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF

MDCX

PRTC

RANI

Absci

ADC Therapeutics

Astria Therapeutics

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences

Emergent BioSolutions

enGene Holdings

ETHZilla

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

I-MAB

Immuneering Corporation - Class A Common Stock

Immuneering

Inhibrx Biosciences

Kamada

Korro Bio

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

ProKidney Corp. - Class A Ordinary Shares

ProKidney

RAPT Therapeutics

Rigel Pharmaceuticals, Inc. - Common Stock

Comments

PureTech Health Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO